CCL Jan 2017 - The Cancer Letter

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Request Cancellation

Renew today!

Your subscription has lapsed. Subscribe today to access this content.

SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.

LOGIN SUBSCRIBE NOW

SEARCH DATE

SEARCH TEXT

Cancel

OK

Cancel

OK

Delete Account

Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below

Study Shows Only Nuclear-Localized AR-V7 Predictive of Benefit for Patients with Metastatic Disease

Early-phase Study Shows Shrinkage in Pediatric Neural Tumors

MammaPrint Substantially Impacts How Breast Cancer in Germany is Treated

Halozyme's Phase II Study In Advanced Pancreas Cancer Meets Endpoints

Cota Study Suggests Some Patients Are Left Behind in Genomic Revolution

NewVac Meets Primary Endpoints in Phase II Trial of Quisinostat Combination in Platinum-Resistant Disease

ONC201 Glioblastoma Trial to Expand Based on Promising Initial Results

Study Finds Biological Explanation for Racial Disparities in Survival for Certain Cancers

NCI CTEP-Approved Trials for January

Tecentriq receives priority review for treatment of urothelial carcinoma

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login